Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Article Title: Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment
doi: 10.1016/j.biopha.2024.117265
Figure Lengend Snippet: α-CD99-A192 increases expression of activation marker CD38 but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, CD25. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.
Article Snippet: Anti-Human CD3 PerCP-Cyanine 5.5 (Clone: OKT3; eBioscience, Cat#45–0037–42), Anti-Human CD38 FITC (Clone: HB7; eBioscience, Cat#11–0388) and Anti-Human CD69 PE (Clone: FN50; eBioscience, Cat#12–0699) was added to the cells.
Techniques: Expressing, Activation Assay, Marker, Flow Cytometry, Control